Physician’s Profile

Angela Kadenhe-Chiweshe, MD

Affiliations: 
NewYork-Presbyterian/Lawrence Hospital
NewYork-Presbyterian/Columbia
NewYork-Presbyterian/Morgan Stanley Children's Hospital
Board Certificates: 
Pediatric Surgery
Surgery
Expertise: 
Thoracic Surgery
Surgery, Gastrointestinal
Minimal Access Surgery
Pediatric Minimal Access Surgery
Honors: 

Blakemore Prize 2004.  Awarded by the Department of Surgery for outstanding research 

Interests: 
Tumor angiogenesis
Mechanisms of resistance to angiogenic therapies
About: 

Dr. Kadenhe-Chiweshe completed her M.D. degree at the Pennsylvania State University College of Medicine. She entered a categorical general surgery residency at the University of Rochester where her interest in pediatric surgery was solidified. In 2001 she joined the Tumor Angiogenesis Research Laboratory run by Jessica Kandel and Darrell Yamashiro as a postdoctoral research fellow.

She spent her time studying the effects of anti-angiogenic therapy in a xenograft model of hepatoblastoma. This work led to key discoveries of how this tumor responds to anti-angiogenic therapy. During this time she also completed an attenuated clinical fellowship in Extra-Corporal Membrane Oxygenation with Charles Stolar. She went on to complete her general surgery training at Columbia University in 2007, followed by a fellowship in Pediatric Surgery at the Children's Hospital of New York in 2009.

Dr. Kadenhe-Chiweshe joined the faculty of the College of Physicians and Surgeons, Columbia University, as Assistant Professor of Surgery in July 2009. Her clinical interest is all general pediatric surgery, in particular neonatal anomalies, minimal access surgery, and pediatric cancer. More information on her work in pediatric vascular formations can be found here. 

Dr. Kadenhe-Chiweshe's academic interests are in the field of basic science research. She continues to study the effects of angiogenic therapies in hepatoblastoma xenografts, with emphasis on understanding the emergence of resistance to these therapies and the mechanisms that govern it.

Publications: 
Initial Experience With Propranolol Treatment of Lymphatic Anomalies: A Case Series. Wu JK, Hooper ED, Laifer-Narin SL, Simpson LL, Kandel J, Shawber CJ; Lymphatics Work Group at CUMC   Pediatrics 2016 Sep;138(3).  https://www.ncbi.nlm.nih.gov/pubmed/27561730
Vascular Anomalies Classification: Recommendations From the International Society for the Study of Vascular Anomalies. Wassef M, Blei F, Adams D, Alomari A, Baselga E, Berenstein A, Burrows P, Frieden IJ, Garzon MC, Lopez-Gutierrez JC, Lord DJ, Mitchel S, Powell J, Prendiville J, Vikkula M; ISSVA Board and Scientific Committee.. Pediatrics 2015 Jul;136(1):e203-14. https://www.ncbi.nlm.nih.gov/pubmed/26055853
Kadenhe-Chiweshe A, Papa J, McCrudden KW, Frischer, Bae JO, Huang J, Fisher J, Lefkowitch JH, Feirt N, Rudge J, Holash J, Yancopoulos GD, Kandel JJ, Yamashiro DJ. Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation. Molecular Cancer Research. 2008 Jan: 6(1):1-9.
Middlesworth WM, Kadenhe-Chiweshe A.Neonatal Intestinal Obstruction Burg/Ingelfinger/Polin/Gershon: Current Pediatric Therapy 18th Revised edition, 2006.
Frischer JS, Huang J, Serur A, Kadenhe-Chiweshe A, McCrudden KW, O’Toole K, Holash J, Yancopoulous GD, Yamashiro DJ, Kandel JJ. Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature. International Journal of Oncology, September 2004. 25 (3): p.549-553.
Frischer JS, Huang J, Serur A, Kadenhe A, Yamashiro DJ, Kandel JJ. Biomolecular markers and involution of hemangiomas. Journal of Pediatric Surgery, March 2004. 39(3): p. 400-4.
Kaicker S, McCrudden KW, Beck L, New T, Huang J, Frischer JS, Serur A, Kadenhe-Chiweshe A, Yokoi A, Kandel JJ, Yamashiro DJ. Thalidomide Is Anti-Angiogenic In A Xenograft Model of Neuroblastoma. International Journal of Oncology, December 2003. 23 (6): p.1651-1656.
Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, New T, O'Toole K, Stolar CJH, Zabski S, et al. Regression of Established tumors and Metastases by potent VEGF Blockade. Proceedings of the National Academy of Science. June 2003. p. 7785-7790.
McCrudden KW, Hopkins B, Frischer J, Novikov A, Huang J, Kadenhe A, New T, Yokoi A. Yamashiro, D.J., Kandel, J.J., Middlesworth, W. Anti-VEGF Antibody in Experimental Hepatoblastoma: Suppression of Tumor Growth and Altered Angiogenesis. Journal of Pediatric Surgery, March 2003. 38(3): p. 308-314.